Gardasil Faces Another Safety Study, Looking At Four Rare AEs
This article was originally published in The Pink Sheet Daily
Sentinel will consider data from 3m doses of Merck's nine-valent HPV vaccine.
You may also be interested in...
Promotion strategy likely to remain same after nine-valent HPV vaccine wins FDA approval; Merck may need help from the CDC to overcome cultural barriers to adoption.
GlaxoSmithKline's effort to make its bivalent human papillomavirus vaccine, Cervarix, into a multivalent product through proof of cross protection against additional HPV virus strains achieved a partial, one-virus, success at FDA
Pink Sheet reporters and editors discuss increasing complete response letters for breakthrough designees, FDA changing course on statin use during pregnancy, and efforts to use pandemic innovations to improve clinical research going forward.